CIK 0001159036 · Large accelerated filer
HALOZYME THERAPEUTICS, INC.
Sign in to watch- Ticker
- HALO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880488686
- Phone
- (858) 794-8889
- Business address
- 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130
- Former names
- HALOZYME THERAPEUTICS INC, GLOBAL YACHT SERVICES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $19,884,955
- in 5 filings, $19.9M under 10b5-1 plans
Net −$19,884,955. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-05 | Lang James Paul Director | Grant or award · Option to Purchase Common Stock | +6,040 | 6,040 | ||
| 2026-05-05 | Henderson Jeffrey William Director | Grant or award | +3,796 | 36,572 | ||
| 2026-05-05 | Henderson Jeffrey William Director | Grant or award · Option to Purchase Common Stock | +6,040 | 6,040 | ||
| 2026-05-05 | DUNCAN BARBARA GAYLE Director | Grant or award | +3,796 | 23,715 | ||
| 2026-05-05 | DUNCAN BARBARA GAYLE Director | Grant or award · Option to Purchase Common Stock | +6,040 | 6,040 | ||
| 2026-05-05 | Connaughton Bernadette Director | Grant or award | +6,796 | 45,294 | ||
| 2026-05-05 | Connaughton Bernadette Director | Grant or award · Option to Purchase Common Stock | +6,040 | 6,040 | ||
| 2026-05-01 | Connaughton Bernadette Director | Sale 10b5-1 | −1,625 | $63.48 | $103K | 38,498 |
| 2026-04-06 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 | +10,000 | $12.07 | $121K | 777,780 |
| 2026-04-06 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −5,900 | $63.14 | $373K | 771,880 |
| 2026-04-06 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −4,100 | $64.02 | $262K | 767,780 |
| 2026-04-06 | Torley Helen PRESIDENT AND CEO | Option exercise · Option to Purchase Common Stock 10b5-1 | −10,000 | $12.07 | $121K | 101,923 |
| 2026-04-02 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 | +20,000 | $12.07 | $241K | 787,780 |
| 2026-04-02 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −15,800 | $64.06 | $1.0M | 771,980 |
| 2026-04-02 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −4,200 | $64.89 | $273K | 767,780 |
| 2026-04-02 | Torley Helen PRESIDENT AND CEO | Option exercise · Option to Purchase Common Stock 10b5-1 | −20,000 | $12.07 | $241K | 111,923 |
| 2026-04-01 | RAMSAY DAVID A Interim CFO | Grant or award · Restricted Stock Units | +10,000 | 10,000 | ||
| 2026-04-01 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 | +20,000 | $12.07 | $241K | 787,780 |
| 2026-04-01 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −19,000 | $65.36 | $1.2M | 768,780 |
| 2026-04-01 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −1,000 | $65.71 | $66K | 767,780 |
Page 7 of 26 · 513 trades